Treatment of Diabetes with L363,586
L363,586 (now referred to as MK-678) is a cyclic hexapeptide analog of somatostatin. This compound, whose amino acid sequence is shown in Figure 1, was developed by chemists at Merck, Sharp and Dohme Research laboratories on the basis of modeling of the active site of the somatostatin molecule in a project which involved the synthesis of more than 150 analogs (1).
KeywordsGrowth Hormone Postprandial Hyperglycemia Regular Insulin Plasma Growth Hormone Postprandial Plasma Glucose
Unable to display preview. Download preview PDF.
- 2.Gottesman I, Tobert J, Vandlen R, Gerich J. Efficacy, pharmacokinetics and tolerability of a somatostatin analog (L363,586) in insulin-dependent diabetes mellitus. Life Sci (in press).Google Scholar
- 4.Campbell P, Bolli G, Gerich J. Prevention of the dawn phenomenon (early morning hyperglycemia) in insulin-dependent diabetes mellitus by a long-acting somatostatin analog. N Engl J Med (in press).Google Scholar